Japan Chronic Cough Therapeutics Market Analysis

Japan Chronic Cough Therapeutics Market Executive Summary

Japan Chronic Cough Therapeutics Market was valued at $392 Mn in 2022 and is estimated to reach $758 Mn in 2030, exhibiting a CAGR of 8.6% during the forecast period.

Chronic cough refers to a persistent cough lasting more than eight weeks, distinguishing it from acute coughs associated with short-term conditions. Unlike short-term coughs often linked to infections, chronic cough can indicate a more enduring underlying health problem. Respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications commonly cause chronic cough. Identifying and addressing the root cause through a thorough medical assessment is essential for effective management. Chronic cough significantly impacts the quality of life, often requiring a comprehensive, multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists.

In Japan, the prevalence of chronic cough stands at 2.89% and 2.9%, with the highest occurrence observed among males aged 60 and above. Asthma, cough variant asthma, and allergic rhinitis are the most commonly occurring related illnesses. These findings underscore the significance of addressing chronic cough, particularly in the elderly male population, and highlight the prevalence of conditions contributing to this symptomatology. The patterns highlight the need for improved care for people with chronic cough in Japan. Also, a need for more research projects and increased efforts in medical education in this particular area to better comprehend and handle the complications related to chronic cough. This collective approach is crucial for advancing patient care and overall respiratory health in the Japanese population.

Positive Phase 1 safety data for ATS-2893 were presented by Akari Therapeutics at the American Thoracic Society meeting, marking a significant advancement in the field of chronic cough treatments. The development of ATS-2893, a nasal spray intended to treat persistent cough, has reached a significant milestone with this accomplishment. Positive safety data support ATS-2893's potential as a promising candidate for additional clinical development, which is a step in the right direction for Akari Therapeutics' search for novel and potent therapies for chronic cough.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Chronic Cough: The exacerbation of respiratory problems is attributed to the rise in urbanization and lifestyle modifications, including smoking and exposure to air pollutants. There is a growing incidence of chronic cough and its associated complications. The elderly demographic, prone to enduring health challenges, is particularly susceptible to ailments such as chronic cough.

Prevalence of Smoking: As of 2022, approximately 18.2 Mn adults aged 15 years and older in Japan were using tobacco products, constituting around 12.2% of the population. Japan exhibits a significant prevalence of smoking, a major factor contributing to respiratory problems such as chronic cough. The need to mitigate the effects of smoking-induced cough has generated a demand for various therapeutic approaches, encompassing smoking cessation programs and specialized treatments designed to address cough associated with smoking.

Rising Awareness and Diagnosis: Growing awareness among both healthcare professionals and the general population regarding the impact of chronic cough on quality of life is leading to increased diagnosis. As awareness improves, more individuals seek medical attention for their chronic cough symptoms, driving the demand for therapeutic interventions.

Market Restraints

Cultural Perceptions and Traditional Remedies: Individuals in Japan may rely on homeopathic or traditional remedies as a result of cultural attitudes and preferences that may affect how persistent coughs are perceived. Persuading medical professionals and patients to adopt contemporary treatment alternatives could pose a constraint on the industry.

Regulatory Hurdles: Stringent regulatory requirements and approval processes in Japan can present difficulties for pharmaceutical companies aiming to introduce new treatments for chronic cough to the market. Navigating complex regulatory frameworks may result in delays in product approvals and market entry.

Affordability and Reimbursement Issues: Economic considerations and divergent extents of insurance coverage might impact the accessibility of chronic cough treatments for certain population segments. Constrained reimbursement alternatives could potentially dissuade individuals from initiating or sustaining their treatment.

Healthcare Policies and Regulatory Landscape

In Japan, the regulatory framework governing therapeutic drugs is overseen by the Pharmaceuticals and Medical Devices Agency (PMDA), responsible for assessing the safety, effectiveness, and quality of pharmaceuticals, including treatment drugs, prior to their approval for market release. The Ministry of Health, Labor, and Welfare (MHLW), in collaboration with the PMDA, holds a central role in shaping healthcare policies and ensuring that drugs adhere to national health standards. Conditional approvals may be granted based on early-stage results, with companies mandated to conduct post-marketing evaluations to gather additional data on drug efficacy and safety. The MHLW is also responsible for overseeing the national health insurance system, influencing coverage, and reimbursement policies for treatment drugs. To foster global collaboration in drug development and distribution, Japanese pharmaceutical companies frequently engage in international partnerships and licensing agreements.

Competitive Landscape

Key Players

• Eisai Co.
• Taisho Pharmaceutical Co.
• Shionogi & Co.
• Daiichi Sankyo Co.
• Sumitomo Dainippon Pharma Co.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi
• Novartis
• GlaxoSmithKline